Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note issued to investors on Sunday morning. The brokerage issued a sell rating on the stock.

Separately, Alliance Global Partners lifted their price objective on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, July 22nd.

Tonix Pharmaceuticals Stock Up 0.3 %

TNXP stock opened at $0.18 on Friday. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $22.14. The company has a current ratio of 1.15, a quick ratio of 0.72 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $24.71 million, a P/E ratio of 0.00 and a beta of 2.08. The firm has a 50 day simple moving average of $0.22 and a 200-day simple moving average of $2.14.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Friday, August 16th. The company reported ($19.28) earnings per share for the quarter, missing the consensus estimate of ($9.91) by ($9.37). The firm had revenue of $2.21 million during the quarter, compared to the consensus estimate of $3.50 million. Tonix Pharmaceuticals had a negative net margin of 1,196.11% and a negative return on equity of 158.27%. On average, equities research analysts predict that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC boosted its stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned approximately 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent reporting period. 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.